



Volume 2, Issue 3
March 2023

Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives E_z - MINUTES

Drugs Added to the VA National Formulary WITHOUT Prior Authorization

- EYELID CLEANSER, EYE SCRUB PAD
- Bypassing agents for patients with Hemophilia A or B and Inhibitors, which include Factor VIIa recombinant jncw (SEVENFACT), Factor VIIa recombinant (NOVOSEVEN RT) and Anti-Inhibitor Coagulation Complex (FEIBA)

Drugs Added to the VA National Formulary WITH Prior Authorization

- Terlipressin (TERLIVAZ)
- Fosfomycin (MONUROL)
- Everolimus tablet

Drugs Not Added to the VA National Formulary

- Bupivacaine-Meloxicam SA Solution (ZYNRELEF)
- Teplizumab-mzww (TZIELD) Injection
- Deferiprone (FERRIPROX) tablets and solution
- Pegfilgrastim-fpgk (STIMUFEND)

Formulary Drugs with Prior Authorization Removed

- Valsartan

Drugs Removed from the VA National Formulary

- none

Other Announcements

- Sharps Container added to VANF
- Semaglutide WEGOVY Criteria Revision
- Liraglutide SAXENDA Criteria Revision
- Weight Management Medications Guidance Revision
- Tafamidis VYNDAMAX VYNDAQEL Criteria Revision
- Tranexamic acid oral LYSTEDA Criteria Revision
- Risankizumab-rzaa (SKYRIZI) in Crohn's Disease Criteria Revision
- Deferasirox EXJADE JADENU Criteria Revision
- CGRP monoclonal antibody Criteria Revisions (erenumab and galcanezumab for cluster headache)
- Ravulizumab (ULTOMIRIS) Criteria revision
- Eculizumab (SOLIRIS) Criteria revision
- Efgartigimod alfa-fcab (VYVGART) Criteria revision
- No Buy and Non-Promotable lists updates made